8-K: INmune Bio Inc. Announces Year End 2024 Results and Provides Business Update

INmune Bio Inc. reported its financial results for the year ended December 31, 2024, and provided a business update, including progress on its DN-TNF, CORDStrom, and INKmune platforms.

Summary

• INmune Bio Inc. announced its financial results for the year ended December 31, 2024, and provided a business update on March 27, 2025.
• The company's DN-TNF platform highlighted the completion of enrollment for its Phase 2 AD02 trial focused on early Alzheimer's Disease, exceeding the target with 208 patients enrolled.
• Interim analyses of the AD02 trial demonstrated exceptional performance of the EMACC cognitive measure and a significant correlation between baseline EMACC and CDR-SB scores (p<0.001).
• CORDStrom received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the FDA for treating epidermolysis bullosa (EB).
• The MissionEB trial showed CORDStrom was well-tolerated in pediatric patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), with some patients experiencing a sustained 27% reduction in itch at 6 months.
• INKmune demonstrated excellent safety and increased NK-Cell activity in the first dosing cohort of its Phase I/II CaRe PC trial for metastatic Castration-Resistant Prostate Cancer (mCRPC).
• The company completed repayment of its outstanding Silicon Valley Bank term loan in December.
• INmune Bio executed securities purchase agreements for approximately $27.5 million in gross proceeds and sold shares through the ATM program for $2.4 million in 2024 and $5.4 million between January 1 and March 27, 2025.
• Top line cognitive results from the AD02 trial are expected in June 2025.
• The company anticipates filing a BLA for CORDStrom in RDEB in 2025 or early 2026.
• The net loss attributable to common stockholders for 2024 was approximately $42.1 million, compared to $30.0 million in 2023.
• Research and development expenses totaled approximately $33.2 million for 2024, compared to $20.3 million in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of approximately $20.9 million.
• As of March 27, 2025, the company had approximately 22.9 million common shares outstanding.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the clinical programs and fundraising efforts, the increased net loss and decreased cash position are concerning.

Positives

• The Phase 2 AD02 trial completed enrollment with more patients than initially targeted.
• The EMACC cognitive measure showed promising results in interim analyses of the AD02 trial.
• CORDStrom received key designations from the FDA, potentially accelerating its development and approval.
• The MissionEB trial demonstrated a favorable benefit-risk profile for CORDStrom in treating RDEB.
• INKmune showed promising early results in the CaRe PC trial, with increased NK-Cell activity and excellent safety.
• The company successfully raised capital through securities purchase agreements and the ATM program.
• The company repaid its outstanding Silicon Valley Bank term loan.

Negatives

• The net loss attributable to common stockholders increased from $30.0 million in 2023 to $42.1 million in 2024.
• Research and development expenses increased from $20.3 million in 2023 to $33.2 million in 2024.
• Cash and cash equivalents decreased from $35.8 million at the end of 2023 to $20.9 million at the end of 2024.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding is crucial for the company to continue its operations and development programs.
• Regulatory approval for the company's product candidates is not guaranteed.
• The company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies are subject to risks and uncertainties.

Future Outlook

The company anticipates top line cognitive results from the AD02 trial in June 2025, data from the INKmune trial in mCRPC in Q2 or Q3 2025, and filing a BLA for CORDStrom in RDEB in 2025 or early 2026.

Industry Context

INmune Bio is operating in the competitive fields of inflammation, immunology, and oncology, focusing on treatments that harness the innate immune system.

Comparison to Industry Standards

• The company's approach of targeting soluble TNF with XPro differs from traditional TNF inhibitors, potentially offering a more targeted treatment for neuroinflammation.
• The development of EMACC as a cognitive measure aims to improve the precision and sensitivity of assessing cognitive changes in early Alzheimer's trials, addressing a key challenge in the field.
• The CORDStrom platform leverages allogeneic MSCs, which is a common approach in cell therapy, but INmune Bio emphasizes its proprietary screening, pooling, and expansion techniques for creating consistent and scalable products.
• The INKmune platform's focus on priming NK cells to target cancer cells aligns with the growing interest in NK cell-based immunotherapies.

Stakeholder Impact

• Shareholders: The financial results and clinical trial updates will impact shareholder value.
• Employees: The company's progress and financial stability affect employee morale and job security.
• Patients: The development of new treatments offers hope for improved outcomes.
• Investors: The company's ability to secure funding and achieve clinical milestones is crucial for investor confidence.

Next Steps

• Release top line cognitive results from the AD02 trial in June 2025.
• Release data from the ongoing INKmune trial in mCRPC in Q2 or Q3 2025.
• Begin enrollment in a Phase II trial of XPro in patients with Treatment-Resistant Depression.
• File a BLA for CORDStrom in RDEB in 2025 or early 2026.

Key Dates

Keywords

INmune Bio, Financial Results, Alzheimer's Disease, CORDStrom, INKmune, Clinical Trial, RDEB, mCRPC, DN-TNF, XPro1595